Literature DB >> 6780629

Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid.

M Porro, M Saletti, L Nencioni, L Tagliaferri, I Marsili.   

Abstract

The in vivo immunizing potency of diphtheria toxoid and formalin-treated corss-reacting material (CRM197, a nontoxic mutant protein) was compared in guinea pigs. Major antigenic differences between the two untreated proteins were also tested in rats. The results showed that diphtheria toxoid and CRM197 were equally effective immunogens, but only if the latter was treated with formalin in the same concentration (0.7% vol/vol) was that of the toxoid. Formalin treatment rendered the antigens more resistant to enzymatic proteolysis by trypsin in vitro.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6780629     DOI: 10.1093/infdis/142.5.716

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Authors:  Joseph A Bellanti; Feng-Ying C Lin; Chiayung Chu; Joseph Shiloach; Stephen H Leppla; German A Benavides; Arthur Karpas; Mahtab Moayeri; Chunyan Guo; John B Robbins; Rachel Schneerson
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

2.  Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.

Authors:  Pavan Muttil; Brian Pulliam; Lucila Garcia-Contreras; John Kevin Fallon; Chenchen Wang; Anthony James Hickey; David A Edwards
Journal:  AAPS J       Date:  2010-09-28       Impact factor: 4.009

3.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity.

Authors:  M Pizza; A Bartoloni; A Prugnola; S Silvestri; R Rappuoli
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.

Authors:  L Nencioni; M Pizza; M Bugnoli; T De Magistris; A Di Tommaso; F Giovannoni; R Manetti; I Marsili; G Matteucci; D Nucci
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

Review 6.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

7.  Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197.

Authors:  R Rappuoli
Journal:  Appl Environ Microbiol       Date:  1983-09       Impact factor: 4.792

8.  The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

Authors:  G Giannini; R Rappuoli; G Ratti
Journal:  Nucleic Acids Res       Date:  1984-05-25       Impact factor: 16.971

9.  Human antibody response to fragments A and B of diphtheria toxin and a synthetic peptide of amino acid residues 141-157 of fragment A.

Authors:  V Y Perera; M J Corbel
Journal:  Epidemiol Infect       Date:  1990-12       Impact factor: 2.451

10.  Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.

Authors:  Benjamin K Quintel; Archana Thomas; Danae E Poer DeRaad; Mark K Slifka; Ian J Amanna
Journal:  Vaccine       Date:  2018-12-31       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.